ALK and gastric cancer: Drug screening studies in isogenic CDH1−/−-mutant mammary epithelial MCF10A and c.1380delA CDH1-mutant gastric cancer cells show considerable overlap in sensitivity to PI3K, mTOR, or ALK/ROS-1 like tyrosine kinase inhibition.